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ALTHOUGH it is now accepted that killer-cell inhibitory
receptors (KIRs), which were molecularly cloned in
1995, deliver negative signals to natural killer (NK)
cells regarding the recognition of target cells, it is still
unclear  how  the  expression  of  these  receptors  on
lymphocytes is regulated. Therefore, we investigated
the regulation of expression of representative KIRs,
CD158a  and  CD158b,  by  cytokines  such  as  inter-
leukin-2 (IL-2), IL-4 and interferon-g (IFN-g ). Neither
IL-4 nor IFN-g affected the expression of CD158a/b,
but incubation for 48h with IL-2, which enhances the
killer activity of NK cells, upregulated the expression
of  the  KIRs.  This  upregulation  by  IL-2  was  also
observed  in  CD16-positive  cells  sorted  from  total
lymphocytes.  In  contrast,  IL-4,  which  is  a  down-
regulator  of  IL-2-induced  killer  responses,  did  not
change the level of CD158a/b expression when added
after the IL-2 treatment. These findings suggest that
IL-2  plays  an  important  role  in  the  regulation  of
CD158a/b  expression,  and  might  be  involved  in
controlling NK activity via regulating expression of
these molecules.
Introduction
It  is  known  that  natural  killer  (NK)  cells  play  an
important role in the biodefense against virus-infected
cells and neoplastic cells. Before it was determined
what molecules NK cells recognize on target cells, it
was  observed  that  target  cells  that  fail  to  express
major histcompatibility complex (MHC) class I mole-
cules are lysed by NK cells.1 In 1995, several groups
reported  the  molecular  cloning of NK receptors2–4
which deliver negative signals that inhibit killing.5,6
It is now widely accepted that NK cells recognize
and  lyse  target  cells  through  the  interplay  of  two
families of receptors.7–9 One family consists of killer-
cell  activating receptors  (KARs) and the other con-
sists  of  killer-cell  inhibitory  receptors  (KIRs). The
activating  signal  can  be  overridden  by  a  dominant
negative  signal  from  a  KIR  when  the  KIR  interacts
with  its  ligand  on  the  target  cell,  although  KARs,
when occupied, trigger lysis of the target cell being
recognized. Thus, it is crucial to analyze the regulation
of  the  expression  of  KIRs  in  order  to  further  our
understanding of killer activity.
Classically, the NK activity assay (51Cr-release assay)
has been used to assess the cytotoxic function of NK
cells. Natural cell-mediated cytotoxicity by NK cells
has been defined as the ability to lyse neoplastic cells
in vitro without definable prior activation. However,
the augmentation of NK activity by several cytokines
has been demonstrated. Interleukin-2 (IL-2) activates
the cytotoxicity,10 induces NK cell proliferation and
stimulates  increased  production  of  granule  con-
tents.11,12 In  contrast, the augmentation of cytotox-
icity by interferon-g (IFN-g ) varies depending on the
subject.13 Interleukin-4 (IL-4) and transforming growth
factor-b (TGF-b ) are reported to be downregulatory
cytokines of IL-2-induced killer responses.14,15
At  present,  the  identification  of  the  KIRs  raises
several interesting questions. How is the expression
of  KIRs  affected  by  cytokines  such  as  IL-2,  which
activates  cytotoxicity,  and  IL-4,  which  inhibits  IL-
2-induced  cytotoxicity?  Answering  these  questions
may yield insights into the process by which NK cells
specifically recognize their target cells when NK cells
are activated during the course of virus infection or
neoplastic disease.
Materials and methods
Reagents
Fluorescein  isothiocyanate  (FITC)-conjugated  anti-
human  CD8,  FITC-anti-human  CD16,  phycoerythrin
(PE)-conjugated  anti-human  CD56,  PE-anti-human
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(GL183)16–19 were  purchased  from  Immunotech
(Marseille,  France).  Hapten-conjugated  anti-human
CD3, CD4, CD19 and CD33 antibodies and colloidal
super-paramagnetic magnetic cell separation (MACS)
microbeads conjugated to anti-hapten antibody were
obtained  from  Miltenyl  Biotec  (Bergisch-Gladbach,
Germany). Recombinant human IL-2, IL-4 and IFN-g
were obtained from Pharmabiotechnology (Hanover,
Germany).
PBMC and NK cell preparation
Peripheral  blood  mononuclear  cells  (PBMC)
obtained  from  14  healthy  donors  were  separated
from heparinized blood by Lymphoprep (Nyegaard,
Oslo, Norway) gradient cenfugation.20 PBMC suspen-
sions  were  washed  twice  in  phosphate-buffered
saline  (PBS).
For  further  immunomagnetic  separation  of  NK
cells  from  the  PBMC  of  six  healthy  subjects,  the
magnetic  cell  separation  (MACS)  system  (Miltenyi,
Biotec,  Bergisch-Gladbach,  Germany)  was  used.21
This method is an indirect magnetic labeling system
for depletion of human T cells, B cells and myeloid
cells  from PBMC  to  enrich  untouched NK  cells.  In
brief,  hapten-conjugated  monoclonal  antibodies
against  CD3,  CD4, CD19  and CD33  were  added to
107 PBMC  suspended  in  80 m l  of  PBS,  mixed  well
and  incubated  for  15 min  at  10°C.  Cells  were
washed carefully with 2ml of PBS and resuspended
in  80 m l  of  PBS.  The  colloidal  super-paramagnetic
MACS  Microbeads  conjugated  to  anti-hapten  anti-
body were added to the cells, and the mixture was
incubated  for  15min  at  10°C.  The  cells  were
washed, collected and suspended in 500 m l of PBS/
5 mM EDTA/0.5% bovine serum albumin (BSA). The
cell suspension was applied to a prefilled depletion
column,  and  the  pass-through  fraction  containing
unlabeled cells was collected and used as the enri-
ched  NK cells.
Cell phenotype
Surface  phenotyping  was  carried  out  with  a  two-
color immunofluorescence staining technique, using
isotype-specific  mouse  anti-human  antibody  conju-
gated  with  either  FITC  or  PE.16 The  stained  cells
were  suspended  in  0.5 ml  of  PBS  per  sample  and
analyzed  by  flow  cytometry  (Epics  XL,  Beckman
Coulter,  France).  Lymphocyte  subsets  were  identi-
fied  by  gating  analysis  and  fluorescence  profiles
obtained  for  10 000  cells  of  each  sample.  Negative
controls for each experiment  were performed with
FITC-  and  PE-labeled  mouse  immunoglobulin-G
(IgG).
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FIG. 1. Two-dimensional flow cytometric  histogram  of  a  representative sample. CD16-FITC is  plotted versus  CD158b-PE.
Sixteen and three-tenths per cent of the lymphocytes were CD16-positive NK cells, of which 40.6% (6.64% of all lymphocytes)
expressed CD158b.Cell culture
One million cells were cultured in RPMI1640 medium
containing 10% fetal calf serum (Biological Industries,
Israel)  in  a  tissue  culture  dish  (Becton  Dickinson,
Flanklin, NJ, USA). The cultures were incubated in a
humidified 5% CO2/95% air atmosphere at 37°C for
48 h. In  the experiment  of  IL-4  addition  after  treat-
ment  with  IL-2,  the  cells  were  first  cultured  in
medium with IL-2 for 24h, then collected and washed
twice  with  PBS.  The  cells  were  resuspended  in
medium  containing  IL-4  and  incubated  at  37°C  for
24 h. Each experiment was carried out in duplicate.
Statistical analysis
All data were collected in a computer database and
analyzed using the StatView-J 4.02 program (Abacus
Concept,  Berkeley,  CA,  USA).  The  Mann–Whitney
u-test  was  performed  for  each  set  of  laboratory
variables.  For  all  statistical  tests,  significance  was
defined as P<0.05.
Results
The expression of CD158a and CD158b
Figure 1 shows the expression of CD158 versus CD16
as  a  marker  for  NK  cells  as  a  scatter  plot  in  a
representative sample. In all samples, CD16-positive
cells  showed  a  bimodal  distribution  of  the  surface
receptors CD158a/b, as can be seen in this subject.
CD8-positive  cells  also  generally  showed  a  bimodal
distribution  of  CD158a/b.  However,  four  samples
showed a trimodal distribution of CD158a. We judged
whether CD158a was positive or not compared with
Upregulation of KIRs by IL-2
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Table 1. The expression on PBMC of KIRs in healthy subjects (n=14)
Cell population Total lymphocytes CD16-positive cells CD8-positive cells
KIRs* CD158a CD158b CD158a CD158b CD158a CD158b
% of Total lymphocytes 2.11±1.46** 6.34±5.10 1.68±1.43 5.52±4.58 1.03±0.58 2.51±1.66
*KIRs: killer inhibitory receptors; **mean±SD.
FIG. 2. Regulation of KIRs on PBMC by several cytokines. The cells were incubated in a humidified 5% CO2/95% air atmosphere
at 37°C for 48h without cytokine, or with IL-2 (50 or 200U/ml), IL-4 (50U/ml), or IFN-g (1000U/ml). Neither IL-4 nor IFN-g affected
the expression of CD158a/b, but IL-2 upregulated their expression on lymphocytes. Asterisks indicate a significant increase
compared to no treatment in each group with a P value of <0.05. Data are shown as the mean (thick bar) ±SD (thin bar).control/mouse-IgG, although cells expressing CD158a
weakly seemed to be functionally similar to CD158a-
negative  cells.  This  discrete  distribution  pattern
enabled reliable quantification of receptor-negative or
positive subpopulations. The expression of CD158a/b
on  various  cell  types  is  summarized  in  Table  1.
CD158a/b were expressed on CD8 positive cells to a
lesser  degree  than  on  CD16-positive  cells.  In  most
samples,  CD158a  was  expressed  on  fewer  CD16-
positive or -negative cells than CD158b. These obser-
vations  are  in  accordance  with  those  made  in
previous studies.22,23
IL-2 upregulates the expression of CD158a and
CD158b
To investigate the regulation of CD158a/b receptors,
we  assessed  their  response  to  stimulation  by  cyto-
kines. First, we investigated the effects of IL-2, IL-4
and  IFN-g on  the  expression  of  CD158a/b  on  the
PBMC. The results are shown in Fig. 2. Neither IL-4
nor IFN-g affected the expression of CD158a/b, but
IL-2 affected their expression on CD16-positive cells.
The  upregulation  by  IL-2  was  observed  to  lesser
degree  in  CD16-negative  cells,  probably  mostly  on
CD8-positive  cells. These  effects  of  IL-2  were  dose-
dependent (data not shown).
Although  IL-4  did  not  change  the  expression  of
these molecules in our study, a previous study showed
that IL-4 is a downregulatory cytokine of IL-2-induced
killer  responses. Therefore,  we  further  investigated
the effects of IL-4 on PBMC treated with IL-2. The level
of expression of CD158a/b after IL-2 stimulation was
not changed by treatment with IL-4, further indicating
that  IL-4  does  not  downregulate  the  expression  of
CD158a/b (Table 2).
IL-2 acts directly on NK cells in the
upregulation of CD158a/b
IL-2  contributes  to T  cell  growth24 in  addition  to
augmenting the killer activity of NK cells. It is thus
possible that the  upregulation of  CD158a/b by  IL-2
is mediated through other cells, especially T cells. To
test this, we treated enriched NK cells with IL-2 and
observed  that  CD158a/b molecules were also upre-
gulated  by  IL-2  in  these  NK  cells,  just  as  in  PBMC
(Table 3).
Discussion
Although  NK  cells  had  been  defined  as TCR/CD3-
negative  cells  that  lyse  neoplastic  or  virus-infected
cells  in  an HLA-unrestricted  manner,  in  contrast  to
the HLA-restricted lysis by T cells, doubts concerning
MHC-unrestricted  recognition  arose  from  the  phe-
nomenon of hybrid resistance in mice and from the
observations that HLA-expressing cell lines are often
more resistant to NK cells than non-HLA expressing
lines.1,25 Subsequently,  the  NK  receptors,  which
recognize  MHC  class  I  molecules  and  deliver  neg-
ative  signals to  NK  cells,  were  identified  in  several
laboratories.26 Based  on  these  findings,  it  is  now
considered  that  NK  activity  may  involve  a  balance
between activating signals from non-self-recognition
and inhibitory ones from self-recognition. However,
it  is  still  unclear  how  this  delicate balance  is regu-
lated. Therefore,  we  investigated  the  regulation  by
cytokines  of  representative  KIRs,  CD158a  and
CD158b,  which  react  with  certain  HLA  molecules
related  to  Cw4,  5,  6  and  Cw1,  3,  7,  8,
respectively.17–19
Our  study  demonstrated  that  expression  of
CD158a/b  molecules  was  upregulated  by  IL-2,  but
not by IFN-g or IL-4. IL-2 is released from T cells, and
in  turn  activates  T  cells.  These  activated  T  cells
release other lymphokines, such as IL-3, IL-5 and IL-
T. Kogure et al.
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Table 2. The effect of IL-4 on the expression of KIRs on PBMC after treatment with IL-2
24h
No treatment IL-2 50U/ml
48h
No treatment IL-2 50U/ml IL-2 50U/ml (first 24h)*
IL-4 50U/ml (last 24h)
CD158a 1.7±0.4 2.4±0.3 1.9±0.2 2.8±1.0 2.4±1.1
(% of lymphocytes)
CD158b 3.7±1.5 6.6±2.8 4.1±1.4 7.8±2.5 6.5±2.7
*The PBMC were cultured in medium containing IL-2 for 24h, and in medium containing IL-4 for the next 24h (See Materials and methods). The
expression of KIRs on PBMC treated with IL-2 followed by IL-4 did not differ from that on PBMC treated with IL-2 alone, suggesting that IL-4 does
not influence the CD158a/b expression after IL-2 treatment.
Table 3. The change of the expression of KIRs when enriched
NK cells are stimulated by IL-2
No treatment IL-2 50U/ml
CD158a 9.0±5.8* 13.9±6.9**
CD158b 23.8±8.1 27.2±9.3**
*Mean±SD (%), n=6; **P<0.05 versus no treatment.6,  in  addition  to  IL-2. There  was  thus  a  possibility
that when PBMC are treated with IL-2, the resulting
upregulation  of  CD158a/b  may  be  dependent  on
cytokines other than  IL-2. To test this, we prepared
NK  cells  from  PBMC  using  the  MACS  system. The
upregulation  of  CD158a/b  molecules  was  also
observed in these enriched NK cells prepared from
PBMC,  suggesting  that  IL-2  is  an  important,  direct
regulator  of  the expression of these molecules.
IL-2 upregulated the KIRs in this study although it
is well known that IL-2 augments cytolytic activity.13
These  facts  seem  to  be  contradictory.  It  is  now
thought that NK activity is dependent on the follow-
ing: (i) the proliferation and sustainment of NK cells,
(ii)  the  augmentation  and  accumulation  of  intra-
cellular  granules,  (iii)  the  expression  of  activating
receptor  or  fas  ligand  on  the  cell  surface,  (iv)  the
blockage of killer potency via inhibitory signals. IL-2
contributes to (i), (ii) and partly to (iii) in activated
NK  cells,  which  have  high  potency  to  lyse  target
cells.  In  our  study,  the  upregulation  of  the  expres-
sion  of  CD16,  activating  receptor,27 was  also
observed by IL-2 treatment. When activated NK cells
lyse virus-infected cells or neoplastic cells, they must
specifically  distinguish  non-MHC  class  I  cells  from
normal cells under the delicate balance required for
specific killing. To this end, the expression of KIRs
may be upregulated on the activated NK cells. IFN-g ,
which  is  also  released  by  activated  NK  cells  and
augments the cytolytic activity of NK cells,13 did not
affect  the  expression  of  these  molecules  in  our
experiments.  A  previous  study  showed  that  IFN-g
upregulated  MHC  class  I  molecules,  which  are  the
ligands of KIRs, on the target cells.28 These observa-
tions lead us to speculate that the augmentation  of
the expression of KIRs on NK  cells along with the
enhancement  of  expression  of  MHC  class  I  mole-
cules on target cells by IFN-g enables activated NK
cells to lyse non-MHC class I cells and to specifically
conserve  MHC  class  I-expressing  cells.  When  this
balance  is  disturbed,  an  attack  on  the  self  by  NK
cells might occur. From the clinical viewpoint, there
might be a failure to express KIRs in  patients with
autoimmune diseases in whom NK cells are upregu-
lated. To confirm this speculation, further studies are
required.
On the other hand, it is known that IL-4 inhibits IL-
2-induced cytotoxity.14,15 We found that IL-4 did not
change the expression of KIRs on NK cells and also
did not affect their expression after treatment with IL-
2.  These  findings  suggest  that  the  suppression  of
cytotoxity by IL-4 is independent of the regulation of
KIR expression. In a recent study, it was demonstrated
that the inhibition of natural cytotoxicity by IL-4 was
due to the inhibition of the induction of granzyme B
expression by IL-2.29
In conclusion, IL-2, but not IFN-g or IL-4, upregu-
lates  the  expression  of  CD158a/b  molecules  on
lymphocytes, suggesting that IL-2 might enhance the
ability of NK cells to distinguish target cells according
to MHC class I expression.
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